Skip to content
My WebMD Sign In, Sign Up
For what it's worth
avatar
blessedladyptl posted:
I thought this might be of interest.


The Anesthetic and Analgesic Drug Products Advisory Committee will meet on December 7, 2012 will discuss the risks and benefits of new drug application (NDA) 202880, by Zogenix Inc., for hydrocodone bitartrate extended-release capsules (proposed trade name Zohydro ER), an opioid analgesic medication for the management of moderate to severe chronic pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. This formulation of hydrocodone bitartrate extended-release capsules represents the first single-entity (i.e., containing no other active pharmaceutical ingredients, such as acetaminophen or ibuprofen) hydrocodone-containing drug product. It will be formulated in dose strengths up to 50 mg, and administered twice daily (i.e., every 12 hours). The committee will be asked to determine whether the benefit-risk assessment of this product favors its approval for marketing.
http://www.fda.gov/AdvisoryCommittees/Calendar/ucm327624.htm?source=govdelivery
Reply


Featuring Experts

David N. Maine, MD is the director of the Center for Interventional Pain Medicine at Mercy Medical Center in Baltimore. Maine graduated with a degree ...More

Helpful Tips

Severe Chronic Pain Lowers Life Expectancy
Previous research has demonstrated a clearly negative influence of chronic pain on health. Now, a new study portrays a profound link ... More
Was this Helpful?
167 of 199 found this helpful

Report Problems to the
Food and Drug Administration

FDAYou are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.